Inga Hoffmann
YOU?
Author Swipe
View article: Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S10 displays differences in celltypes between the cohorts A) for LTS and B) for STS based on CIBERSORT results.
View article: Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
The Table S1 shows the Patient ID, Cancer Stage and the Residual _Tumor status of the TCGA paired cohort grouped by the Survival Group.
View article: Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S4 displays the characteristics and subtypes of the Charité cohort.
View article: Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S5 depicts the BRCA1/2, KRAS Status and HRD-Scores in LTS and STS in the Charité Cohort.
View article: Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S1 shows a REMARK Diagram of the Charité Cohort construction.
View article: Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S2 displays the Proportions of Molecular subtypes of LTS and STS in the Charité cohort and n the TCGA cohort.
View article: Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Purpose:The late-stage diagnosis and the aggressiveness of high-grade serous tubo-ovarian carcinoma (HGSC) often result in poor survival outcomes, yet some patients exhibit an exceptionally long survival rate. This study aimed to identify …
View article: Figure S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S5 shows Candidate Genes in the Charité Cohort and Correlations among candidate genes and Literature research results for candidate genes.
View article: Figure S7 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S7 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S7 shows the Mutation Landscape of TCGA LTS and STS Patients.
View article: Figure S6 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S6 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S6 presents Boxplots showing differences in BRCA1/2, KRAS, RB1, CCNE1 expression between LTS and STS in the Charité cohort.
View article: Table S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S3 shows the likelihoods estimated by ConsensusOV for the subtypes of Charité STS and LTS.
View article: Table S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S2 shows the settings for digital image analysis in QuPath for the three IHC markers (CD3,CD4, CD8)
View article: Figure S8 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S8 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S8 depicts GSEA for Millstein sub-signatures in the Charité cohort. Gene sets were incrementally increased by one gene at thetime (see color code). X-axis shows the NES and only the full 101-gene signature was significantly enriched.
View article: Figure S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S3 shows the Gene count Distribution before and after quality filtering in the Charité Cohort and in the TCGA subcohort.
View article: Figure S9 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S9 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S9 shows CIBERSORT estimated celltypes per sample in the Charité cohort and in the TCGA cohort.
View article: Figure S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S4 shows the results of the DEG Analysis in the TCGA cohort A. DEGs in the TCGA (red = up in STS, blue = up in LTS) cohort B. Volcano plot
View article: Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer Open
BACKGROUND: The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) plays a crucial role in regulating the immune system's response to tumors, but its exact role in cancer, especially in high-grade serous ovarian cancer (HGSOC), remains controvers…
View article: DNA methylation-based classification of sinonasal tumors
DNA methylation-based classification of sinonasal tumors Open
The diagnosis of sinonasal tumors is challenging due to a heterogeneous spectrum of various differential diagnoses as well as poorly defined, disputed entities such as sinonasal undifferentiated carcinomas (SNUCs). In this study, we apply …
View article: Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer
Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer Open
RGS2 regulates G-protein signaling by accelerating hydrolysis of GTP and has been identified as a potentially druggable target in carcinomas. Since the prognosis of patients with high-grade serous ovarian carcinoma (HGSOC) remains utterly …
View article: Mucosal melanomas of different anatomic sites share a common global <scp>DNA</scp> methylation profile with cutaneous melanoma but show location‐dependent patterns of genetic and epigenetic alterations
Mucosal melanomas of different anatomic sites share a common global <span>DNA</span> methylation profile with cutaneous melanoma but show location‐dependent patterns of genetic and epigenetic alterations Open
Cutaneous, ocular, and mucosal melanomas are histologically indistinguishable tumors that are driven by a different spectrum of genetic alterations. With current methods, identification of the site of origin of a melanoma metastasis is cha…
View article: The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases
The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases Open
Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set…
View article: The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases
The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases Open
Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set…
View article: The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases
The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases Open
Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set…
View article: The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases
The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases Open
Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set…
View article: Substituted 2-(2-Aminopyrimidin-4-Yl)Pyridine-4-Carboxylates as Potent Inhibitors of Jumonjic Domain-Containing Histone Demethylases
Substituted 2-(2-Aminopyrimidin-4-Yl)Pyridine-4-Carboxylates as Potent Inhibitors of Jumonjic Domain-Containing Histone Demethylases Open
Virtual screening and rational structural optimization led to a novel scaffold for highly potent and selective JMJD2A inhibitors.